European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
 - EconoTimes)
NEW YORK, April 10, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioAmber Inc. (NYSE:BIOA) who purchased shares pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017; and/or (2) on the open market from January 23, 2017 through March 16, 2017. The action, which was filed in the United States District Court for the Northern District of California, alleges that the Company violated federal securities laws.
The complaint alleges that throughout the Class Period BioAmber made materially false and/or misleading statements and/or failed to disclose that: (1) a large customer of BioAmber that was expected to purchase $2.8 million of succinic acid in Q4 2016 experienced a technical problem in its manufacturing facility and postponed the order to 2017; and (2) as a result, defendants’ statements about BioAmber’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in BioAmber you have until May 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/bioamber-inc.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
